ArticleCells2022

eIF4A/PDCD4 Pathway, a Factor for Doxorubicin Chemoresistance in a Triple-Negative Breast Cancer Cell Model.

Alina González-Ortiz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.